Stockscreener 앱 받기
8.50
1.74%
0.17
Ars Pharmaceuticals Inc 주식(SPRY)의 최신 뉴스
ARS Pharmaceuticals (SPRY) Securities Fraud InvestigationLevi & Korsinsky - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ARS Pharmaceuticals, Inc. (SPRY) And Encourages Stockholders to Connect - ACCESS Newswire
SPRY Should I Buy - Intellectia AI
ARS Pharmaceuticals (SPRY) President awarded 898,456 long-term stock options - Stock Titan
ARS Pharmaceuticals plunges 23% as Neffy fails to secure insurance coverage - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ARS Pharmaceuticals, Inc. (ARS) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraud - Business Wire
SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Encourages ARS Pharmaceuticals - The National Law Review
(SPRY) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
ARS Pharmaceuticals, Inc.(NasdaqGM: SPRY) dropped from Russell 2000 Defensive Index - marketscreener.com
ARS Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of ARS Pharmaceuticals (SPRY) - PR Newswire
Micron Stock And 2 Fast Growth Picks With Major Catalysts Ahead - Sahm
ARS Pharmaceuticals (SPRY) Is Down 11.5% After Losing Spots in Key Russell 2000 Defensive Indices - Yahoo Finance
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2000 Growth-Defensive Index - marketscreener.com
SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Levi & Korsinsky Announces Investigation of Securities Claims Against ARS Pharmaceuticals, Inc. (SPRY) - ACCESS Newswire
Price to earnings forward of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY - TradingView
Enterprise value to revenue forward of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY - TradingView
Form 4 ARS Pharmaceuticals Inc For: 26 June By Investing.com - Investing.com Nigeria
Price to earnings forward of ARS Pharmaceuticals, Inc. – BOATS:SPRY - TradingView
Price to sales forward of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY - TradingView
ARS Pharmaceuticals (NASDAQ: SPRY) grants 30,000 options to RA Capital-linked director - Stock Titan
ARS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director RA CAPITAL MANAGEMENT, L.P.moomoo - Moomoo
Director Rajeev Dadoo granted 30,000 ARS Pharmaceuticals (SPRY) stock options - Stock Titan
ARS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Dadoo Rajeev - Moomoo
Director at ARS Pharmaceuticals (SPRY) receives 30,000 stock options - Stock Titan
ARS Pharmaceuticals (SPRY) director receives grant of 30,000 stock options at $10.54 - Stock Titan
ARS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Kelly Michael - Moomoo
ARS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Islam Saqib - Moomoo
ARS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director SCHNEIDER PHILLIP M - Moomoo
Enterprise value to EBITDA forward of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY - TradingView
Enterprise value to EBITDA forward of ARS Pharmaceuticals, Inc. – BOATS:SPRY - TradingView
Enterprise value to revenue forward of ARS Pharmaceuticals, Inc. – BOATS:SPRY - TradingView
Price to book forward of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY - TradingView
Price to sales forward of ARS Pharmaceuticals, Inc. – BOATS:SPRY - TradingView
Enterprise value to EBIT forward of ARS Pharmaceuticals, Inc. – BOATS:SPRY - TradingView
Gold Gains Over 1%; Fed's Preferred Inflation Gauge Surges To 3-Year High - Sahm
Shareholders at ARS Pharmaceuticals (SPRY) back board, auditor and annual say-on-pay - Stock Titan
ARS Pharma: Strong Growth Meets A Coverage Wall (NASDAQ:SPRY) - Seeking Alpha
ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins - Benzinga
William Blair Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating - Moomoo
ARS Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SPRY) - TradingView
Cantor Fitzgerald keeps Overweight on ARS Pharmaceuticals stock By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
SPRY Forecast — Price Target — Prediction for 2027 - TradingView
Cantor Fitzgerald keeps Overweight on ARS Pharmaceuticals stock - Investing.com
ARS Pharmaceuticals Updates Neffy Coverage Outlook, Cuts 2026 Costs - marketscreener.com
ARS Pharmaceuticals Inc (SPRY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ARS Pharmaceuticals (SPRY) Stock Sinks After-Hours After Commercial Update On Neffy Coverage - Benzinga
SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today - TradingView
ARS Pharmaceuticals lowers 2026 expenses, no new payer wins - Investing.com UK
Stocks to Watch: Micron, ARS Pharmaceuticals, MillerKnoll, Passage Bio - Moomoo
Shares of ARS Pharmaceuticals Fall After No New Commercial Insurers Add Neffy - Moomoo
1.53%
3.59%
자본화:
|
볼륨(24시간):